Treatment strategies for central nervous system infections: An update

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 2, 2015, Pages 187-203

  Tan, Ying Ching ^a   Gill, Arshdeep Kaur ^a   Kim, Kwang Sik ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; Antimicrobial therapy; Bacterial meningitis; Blood brain barrier; Cerebrospinal fluid; Dexamethasone; Escherichia coli; Group B streptococcus; Haemophilus influenzae type b; Listeria monocytogenes; Neisseria meningitidis; Neurologic sequelae; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CORTICOSTEROID; DAPTOMYCIN; GLYCEROL; LINEZOLID; MEROPENEM; MOXIFLOXACIN; POLYSACCHARIDE VACCINE; TELAVANCIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL VACCINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CHEMOPROPHYLAXIS; COGNITIVE DEFECT; CORTICOSTEROID THERAPY; HAEMOPHILUS INFLUENZAE TYPE B; HEARING IMPAIRMENT; HUMAN; NEISSERIA MENINGITIDIS; NERVE CELL LESION; PATHOGENESIS; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; VACCINATION; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG COMBINATION; DRUG EFFECTS; HAEMOPHILUS INFLUENZAE; HEARING LOSS; MENINGITIS, BACTERIAL; NERVE CELL; PATHOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; COGNITION DISORDERS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HAEMOPHILUS INFLUENZAE; HEARING LOSS; HUMANS; MENINGITIS, BACTERIAL; NEISSERIA MENINGITIDIS; NEURONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84921032154     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.973851     Document Type: Review

References (119)

1. Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis 2010;10(1):32-42
2. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(5):317-28
3. Wall EC, Everett DB, Mukaka M, et al. Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type b vaccination, 2000-2012. Clin Infect Dis 2014;58(10):e137-e45
4. Okike IO, Ribeiro S, Ramsay ME, et al. Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study. Lancet Infect Dis 2014;14(4):301-7
5. Meningitis in Burkina Faso, Chad, Niger, Nigeria and Ghana: 2010 epidemic season. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/ Health Section of the Secretariat of the League of Nations. 2011;86(15):143-51
6. Pellegrino P, Carnovale C, Perrone V, et al. Epidemiological analysis on two decades of hospitalisations for meningitis in the United States. Euro J Clin Microbiol Infect Dis 2014;39:1-6
7. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. New Engl J Med 2011;364(21):2016-25
8. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27:B51-63
9. Shao Z, Li W, Ren J, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 2006;367(9508):419-23
10. Whitney AM, Coulson GB, von Gottberg A, et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol 2009;47(9):2787-93
11. Daugla D, Gami J, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet 2014;383(9911):40-7
12. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17(5):840-7
13. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009(4):CD004977
14. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013;31(52):6232-8
15. Ladhani SN, Ramsay M, Slack MP. The impact of Haemophilus influenzae serotype B resurgence on the epidemiology of childhood invasive Haemophilus influenzae disease in England and Wales. Pediatr Infect Dis J 2011;30(10):893-5
16. Scott S, Altanseseg D, Sodbayer D, et al. Impact of Haemophilus influenzae Type b Conjugate Vaccine in Mongolia: prospective Population-Based Surveillance, 2002-2010. J Pediatr 2013;163(1):S8-S11
17. Ladhani S, Slack MP, Heys M, et al. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008;93(8):665-9
18. Bruce MG, Zulz T, DeByle C, et al. Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011. Emerg Infect Dis 2013;19(6):932-7
19. Domingo P, Pomar V, de Benito N, et al. The spectrum of acute bacterial meningitis in elderly patients. BMC Infect Dis 2013;13(1):108
20. Hofinger D, Davis LE. Bacterial meningitis in older adults. Curr Treat Options Neurol 2013;15(4):477-91
21. Fouad R, Khairy M, Fathalah W, et al. Role of clinical presentations and routine CSF analysis in the rapid diagnosis of acute bacterial meningitis in cases of negative gram stained smears. J Trop Med 2014;2014:213762
22. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010;23(3):467-92
23. Shin SH, Kim KS. Treatment of bacterial meningitis: an update. Expert Opin Pharmacother 2012;13(15):2189-206
24. Tzanakaki G, Tsopanomichalou M, Kesanopoulos K, et al. Simultaneous single-tube PCR assay for the detection of Neisseria meningitidis, Haemophilus influenzae type b and Streptococcus pneumoniae. Clin Microbiol Infect 2005;11(5):386-90
25. Wu HM, Cordeiro SM, Harcourt BH, et al. Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis. BMC Infect Dis 2013;13:26
26. Thomas JD, Hatcher CP, Satterfield DA, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One 2011;6(5):e19361
27. Chanteau S, Dartevelle S, Mahamane AE, et al. New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y. PLoS Med 2006;3(9):e337
28. Terrade A, Collard J-M, Nato F, Taha MK. Laboratory evaluation of a rapid diagnostic test for Neisseria meningitidis serogroup A. Trans R Soc Trop Med Hyg 2013;107(7):460-1
29. Bocia¸ga-Jasik M, Garlicki A, Cies̈la A, et al. The diagnostic value of cytokine and nitric oxide concentrations in cerebrospinal fluid for the differential diagnosis of meningitis. Adv Med Sci 2012;57(1):142-7
30. Mukai AO, Krebs VL, Bertoli CJ, Okay TS. TNF-alpha and IL-6 in the diagnosis of bacterial and aseptic meningitis in children. Pediatr Neurol 2006;34(1):25-9
31. López-Cortés LF, Cruz-Ruiz M, Gómez-Mateos J, et al. Measurement of levels of tumor necrosis factor-alpha and interleukin-1 beta in the CSF of patients with meningitis of different etiologies: utility in the differential diagnosis. Clin Infect Dis 1993;16(4):534-9
32. Prasad R, Kapoor R, Srivastava R, et al. Cerebrospinal fluid TNF-alpha, IL-6, and IL-8 in children with bacterial meningitis. Pediatr Neurol 2014;50(1):60-5
33. Akalin H, Akdiş AC, Mistik R, et al. Cerebrospinal fluid interleukin-1 beta/interleukin-1 receptor antagonist balance and tumor necrosis factor-alpha concentrations in tuberculous, viral and acute bacterial meningitis. Scand J Infect Dis 1994;26(6):667-74
34. Hsieh CC, Lu JH, Chen SJ, et al. Cerebrospinal fluid levels of interleukin-6 and interleukin-12 in children with meningitis. Childs Nerv Syst 2009;25(4):461-5
35. López-Cortés LF, Cruz-Ruiz M, Gómez-Mateos J, et al. Interleukin 6 in cerebrospinal fluid of patients with meningitis is not a useful diagnostic marker in the differential diagnosis of meningitis. Ann Clin Biochem 1997;34(Pt 2):165-9
36. Vázquez JA, Adducci Mdel C, Coll C, et al. Acute meningitis prognosis using cerebrospinal fluid interleukin-6 levels. J Emerg Med 2012;43(2):322-7
37. Takahashi W, Nakada TA, Abe R, et al. Usefulness of interleukin 6 levels in the cerebrospinal fluid for the diagnosis of bacterial meningitis. J Crit Care 2014;29(4):693; e1-6
38. Ostergaard C, Benfield TL, Sellebjerg F, et al. Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. Eur J Clin Microbiol Infect Dis 1996;15(2):166-9
39. Konstantinidis T, Cassimos D, Gioka T, et al. Can Procalcitonin in Cerebrospinal Fluid be a Diagnostic Tool for Meningitis? J Clin Lab Anal 2014. [Epub ahead of print]
40. Alkholi UM, Al-monem NA, El-Azim AA, et al. Serum procalcitonin in viral and bacterial meningitis. J Glob Infect Dis 2011;3(1):14
41. Sakushima K, Hayashino Y, Kawaguchi T, et al. Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis. J Infect 2011;62(4):255-62
42. Huy NT, Thao NT, Diep DT, et al. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. Crit Care 2010;14(6):R240
43. Guiddir T, Deghmane A-E, Giorgini D, et al. Lipocalin 2 in cerebrospinal fluid as a marker of acute bacterial meningitis. BMC Infect Dis 2014;14(1):276
44. Lippi G, Avanzini P, Calzetti C, et al. The role of neutrophil gelatinase-associated lipocalin (NGAL) in cerebrospinal fluids for screening of acute bacterial meningitis. Clin Lab 2013;60(3):377-81
45. Bishara J, Hadari N, Shalita-Chesner M, et al. Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults. Euro J Clin Microbiol Infect Dis 2007;26(9):647-50
46. Determann RM, Weisfelt M, de Gans J, et al. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Intensive Care Med 2006;32(8):1243-7
47. Linder A, A˚kesson P, Brink M. et al. Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. Crit Care Med 2011;39(4):812-17
48. Gazzolo D, Grutzfeld D, Michetti F, et al. Increased S100B in cerebrospinal fluid of infants with bacterial meningitis: relationship to brain damage and routine cerebrospinal fluid findings. Clin Chem 2004;50(5):941-4
49. Morichi S, Kashiwagi Y, Takekuma K, et al. Expressions of brain-derived neurotrophic factor (BDNF) in cerebrospinal fluid and plasma of children with meningitis and encephalitis/encephalopathy. Int J Neurosci 2012;123(1):17-23
50. Oliveira CR, Morriss MC, Mistrot JG, et al. Brain Magnetic Resonance Imaging of Infants with Bacterial Meningitis. J Pediatr 2014;165(1):134-9
51. Recommended immunization schedules for persons aged 0 through 18 years - United States, 2010. MMWR 2014;58(51&52):1-4
52. MacNeil JR, Rubin L, McNamara L, et al. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR 2014;63(24):527-30
53. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2013;62(25):521-4
54. Briere EC, Rubin L, Moro PL, et al. Prevention and Control of Haemophilus influenzae Type b Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2014;63:1-14
55. van de Beek D, Brouwer MC, Thwaites GE, et al. Advances in treatment of bacterial meningitis. Lancet 2012;380(9854):1693-702
56. Prasad K, Karlupia N, Kumar A. Treatment of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med 2009;103(7):945-50
57. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillinnon-susceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006;34(11):2758-65
58. Lutsar I, McCracken GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998;42(10):1117-27
59. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010;23(4):858-83
60. Spector R. Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J Neurochem 2010;112(1):13-23
61. Roberts J, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009;37:2071-8
62. Pelkonen T, Roine I, Cruzeiro M, et al. Slow initial beta-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infect Dis 2011;11:613-21
63. Nau R, Djukic M, Spreer A, et al. Bacterial meningitis: new therapeutic approaches. Exp Rev Anti Infect Ther 2013;11(10):1079-95
64. Boyer-Mariotte S, Duboc P, Bonarci S, et al. CTX-M-15-producing Escherichia coli in fatal neonatal meningitis: failure of empirical chemotherapy. J Antimicrob Chemother 2008;62:1472-4
65. Fakioglu E, Queenan AM, Bush K, et al. AmpC beta-lactamase producing E. coli in neonatal meningitis: diagnostic and therapeutic challenge. J Perinatol 2006;26:515-17
66. Houdouin V, Bonacorsi S, Bidet P, Bingen E. Antimicrobial susceptibility of 136 Escherichia coli isolates from cases of neonatal meningitis and relationship with virulence. Clin Microbiol Infect 2007;13:1207-10
67. Colpan A, Porter S, Johnston B, et al. Escherichia coli sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. Veterans. Clin Infect Dis 2013;57:1256-65
68. Ma L, Siu LK, Lin JC, et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC Infect Dis 2013;13:599
69. Saez-Llorens X, Castano E, Garcia R, et al. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995;39(4):937-40
70. Chatellier D, Jourdain M, Mangalaboyi J, et al. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002;28(2):214-17
71. Capparelli FJ, Diaz MF, Hlavnika A, et al. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology 2005;65(11):1840
72. Stucki A, Cottagnoud M, Acosta F, et al. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (beta-lactamase positive and beta-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model. Antimicrob Agents Chemother 2012;56(2):921-5
73. Stucki A, Acosta F, Cottagnoud M, et al. Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model. Antimicrob Agents Chemother 2013;57(12):5808-10
74. Mook-Kanamori B, Rouse M, Kang C-I, et al. Daptomycin in experimental murine pneumococcal meningitis. BMC Infect Dis 2009;9(1):50
75. Gerber P, Stucki A, Acosta F, et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006;57(4):720-3
76. Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004;48(10):3928-33
77. Vivas M, Force E, Garrigos C, et al. Experimental study of the efficacy of daptomycin for the treatment of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 2014. [Epub ahead of print]
78. Spanjaard L, Vandenbroucke-Grauls CM. Activity of Daptomycin against Listeria monocytogenes Isolates from Cerebrospinal Fluid. Antimicrob Agents Chemother 2008;52(5):1850-1
79. Grandgirard D, Oberson K, Bühlmann A, et al. Attenuation of Cerebrospinal Fluid Inflammation by the Nonbacteriolytic Antibiotic Daptomycin versus That by Ceftriaxone in Experimental Pneumococcal Meningitis. Antimicrob Agents Chemother 2010;54(3):1323-6
80. Barichello T, Goncalves JC, Generoso J, et al. Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis. BMC Neurosci 2013;14(1):42
81. Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46(3):936-7
82. Mueller SW, Kiser TH, Anderson TA, et al. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain - associated ventriculitis due to vancomycin-resistant enterococcus faecium. Ann Pharmacother 2012;46(12):e35
83. Watanabe S, Tanaka A, Ono T, et al. Treatment with linezolid in a neonate with meningitis caused by methicillin-resistant Staphylococcus epidermidis. Europ J Pediatr 2013;172(10):1419-21
84. Sipahi OR, Bardak-Ozcem S, Turhan T, et al. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis. Surg Infect (Larchmt) 2013;14(4):357-62
85. Marshall SH, Donskey CJ, Hutton-Thomas R, et al. Gene Dosage and Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002;46(10):3334-6
86. Morales G, Picazo JJ, Baos E, et al. Resistance to Linezolid Is Mediated by the cfr Gene in the First Report of an Outbreak of Linezolid-Resistant Staphylococcus aureus. Clin Infect Dis 2010;50(6):821-5
87. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4(8):528-31
88. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a Novel Lipoglycopeptide. Clin Infect Dis 2009;49(12):1908-14
89. Stucki A, Gerber P, Acosta F, et al. Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters. Antimicrob Agents Chemother 2006;50(2):770-3
90. Alffenaar JWC, van Altena R, Bökkerink HJ, et al. Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis. Clin Infect Dis 2009;49(7):1080-2
91. Rodriguez-Cerrato V, McCoig CC, Michelow IC, et al. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 2001;45(11):3092-7
92. Sipahi OR, Turhan T, Pullukcu H, et al. Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J Antimicrob Chemother 2008;61(3):670-3
93. Østergaard C, Klitmøller Sørensen T, Dahl Knudsen J, et al. Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a Penicillin Resistant Pneumococcus in Rabbits. Antimicrob Agents Chemother 1998;42(7):1706-12
94. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009;9(4):245-55
95. Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010;29(4):379-81
96. Fritz DM, Brouwer MC, van de Beek D. Dexamethasone and long-term survival in bacterial meningitis. Neurology 2012;79(22):2177-9
97. Brouwer MC, McIntyre P, Prasad K, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2013;6:Cd004405
98. Stephen LL, Chris H, Yoeng-Delphine B, et al. Dexamethasone Aggravates Hippocampal Apoptosis and Learning Deficiency in Pneumococcal Meningitis in Infant Rats. Pediatr Res 2003;54(3):353-7
99. Spreer A, Gerber J, Hanssen M, et al. Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr Res 2006;60(2):210-15
100. Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis 2011;11(4):293-300
101. Wall EC, Ajdukiewicz KM, Heyderman RS, et al. Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database Syst Rev 2013;3:Cd008806
102. Spreer A, Gerber J, Baake D, et al. Antiinflammatory but no neuroprotective effects of melatonin under clinical treatment conditions in rabbit models of bacterial meningitis. J Neurosci Res 2006;84(7):1575-9
103. Wu UI, Mai FD, Sheu JN, et al. Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats with acute Klebsiella pneumoniae meningitis. J Pineal Res 2011;50(2):159-70
104. Mourvillier B, Tubach F, van de Beek D, et al. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA 2013;310(20):2174-83
105. Barichello T, Generoso JS, Simoes LR, et al. Vitamin B6 prevents cognitive impairment in experimental pneumococcal meningitis. Exp Biol Med (Maywood) 2014;239(10):1360-5
106. Kim KS. Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat Rev Neurosci 2003;4(5):376-85
107. Gerber J, Nau R. Mechanisms of injury in bacterial meningitis. Curr Opin Neurol 2010;23(3):312-18
108. Gerber J, Brück W, Stadelmann C, et al. Expression of Death-related Proteins in Dentate Granule Cells in Human Bacterial Meningitis. Brain Pathol 2001;11(4):422-31
109. Merchant SN, Gopen Q. A human temporal bone study of acute bacterial meningogenic labyrinthitis. Am J Otol 1996;17(3):375-85
110. Ramakrishnan M, Ulland AJ, Steinhardt LC, et al. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med 2009;7:47
111. Stockmann C, Ampofo K, Byington CL, et al. Pneumococcal Meningitis in Children: epidemiology, Serotypes, and Outcomes From 1997-2010 in Utah. Pediatrics 2013;132(3):421-8
112. Kim KS. Mechanisms of microbial traversal of the blood-brain barrier. Nature Rev Microbiol 2008;6(8):625-34
113. Bernard SC, Simpson N, Join-Lambert O, et al. Pathogenic Neisseria meningitidis utilizes CD147 for vascular colonization. Nat Med 2014;20(7):725-31
114. Coureuil M, Lecuyer H, Scott MG, et al. Meningococcus Hijacks a beta2-adrenoceptor/beta-Arrestin pathway to cross brain microvasculature endothelium. Cell 2010;143(7):1149-60
115. Rijneveld AW, Weijer S, Florquin S, et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis 2004;189(4):711-16
116. Iovino F, Orihuela CJ, Moorlag HE, et al. Interactions between blood-borne Streptococcus pneumoniae and the blood-brain barrier preceding meningitis. PLoS One 2013;8(7):e68408
117. Maruvada R, Kim KS. IbeA and OmpA of Escherichia coli K1 exploit Rac1 activation for invasion of human brain microvascular endothelial cells. Infect Immun 2012;80(6):2035-41
118. Seo HS, Mu R, Kim BJ, et al. Binding of glycoprotein Srr1 of Streptococcus agalactiae to fibrinogen promotes attachment to brain endothelium and the development of meningitis. PLoS Pathog 2012;8(10):e1002947
119. Magalhães V, Andrade EB, Alves J, et al. Group B streptococcus hijacks the host plasminogen system to promote brain endothelial cell invasion. PLoS One 2013;8(5):e63244